Words are hard. Here's how to pick the best ones to use to better communicate your science-based startup's mission. Miguel Tovar/University of Houston

So you're a researcher. Communicating science to a non-scientific audience scares the chemistry out of you.

You've spent your entire career studying fungiform papillae density. The mere thought of fungiform papillae density gives you a rush that even love cannot provide. You know everything about fungiform papillae density. One day you have an interview with a reporter. You're preparing to present at a conference for shareholders. You're writing a grant application. Or you're just at the family cookout and your crazy Uncle Joe with the glass eye wants to know what you do for work.

It's time.

This is the moment where you have to reach deep within yourself to scrape every bit of communications skill in your body. It's time to do what has challenged even the most brilliant scientific minds for ages: explain your work simply.

Yes, there is difficulty in simplicity. The irony is as rich as it is tragic.

Thankfully, there is hope. There are plenty of things you can do to ensure your message is communicated effectively to your non-scientific audience.

Communicating science with better word choices

The old '80s band Missing Persons once sang, "What are words for, when no one listens anymore?"

If what you're saying is not engaging, direct, or simple to understand, your listener will stop listening. The same thing is true for writing.

The words you use matter. They determine whether or not your audience will lock on to what you're trying to convey. Use language that is clear and simple and registers your message.

Personal pronouns like I, you, we help connect readers with the writer and his or her message. Such pronouns present your writing as more of a conversation. People tend to invest more in a conversation than a research paper. Conversations are natural and everyone understands them because everyone is experienced with them. The same cannot be said for research papers about, say, the role of lactic acid production by probiotic Lactobacillus species.

Let's look at the pronouns in action. In the first sentence, you'll see an unnecessarily long, bombastic, impersonal message. In the second, you'll find a more personable, inviting message:

Investigators with supplemental queries or interest in funding opportunities should contact the program.

Contact us if you are interested in funding opportunities.

Words are choice

Your word choices are vital in helping your readers digest your material. Choosing the appropriate words in communicating science stories can not only capture your readers' attention, but keep it.

Use positive words over negative ones. Negative words like don't or not can confuse readers.

Consider this sentence: "The machine doesn't run if you don't follow these instructions exactly as they are written."

It's confusing, isn't it?

Let's rework it with positive words: "The machine will run better if you follow these instructions exactly."

Now there's a sentence that inspires hope.

Inclusive language also helps everyone feel engaged. Stay away from male only pronouns like he and his. Unless you're writing a research paper specifically about men, it's always better to use inclusive language so that non-male readers can follow along and become invested in what you're communicating.

Simple sentences

Using direct, efficiently constructed sentences well get your point across most effectively. According to the search engine optimization platform Yoast, you should keep your sentences under 20 words. Keeping it short with no more than two punctuation points in the body of the sentence will help the reader understand your message. It lets them breathe. It's not overwhelming when it's short.

Make sure to keep your sentences simple, too. Make sure you only cover one idea in every sentence. Keep each paragraph centered on one theme only. Introducing more than one idea or theme will dilute the focus a reader has, because he or she has to divide their attention to give to more things.

Cut the fat. You don't need intensifiers like very, really, actually, or carefully in communicating science stories. They don't really have a purpose. If something is hot and you want to emphasize that point, don't describe it as "really hot." Instead, say that it's "dangerously hot." Say that people have been hospitalized from touching this hot thing. Now you're really saying something.

Verbs with a vengence

Summon the absolute power of verbs.

"Frankie broke the guitar" is a much more vivid portrayal of what happened than "The guitar was broken by Frankie."

Passive voice is often used in a not-so-creative way to hide wrongdoing.

"The money was taken."

Who took the money? The reader might conclude that the writer is hiding something.

"The store manager took the money."

Now you're telling us something we can use. Arrest the store manager.

What you just witnessed is the difference between passive voice (the former) and the active voice (the latter).

It's undeniable that the choices you make with your words and sentences can either connect or kill your audience's interest. They can make the process of communicating science easier or put the brakes on.

Making your technical paper a casual conversation without compromising the integrity of your research helps the lay audience follow along. Using active voice over passive voice helps your readers maintain interest because you're showing a sense of action where someone is doing something. Using universal pronouns expands your reach because everyone can feel they can invest in your writing. Hope is not lost. You can communicate even the most arcane material to the least scientific audiences.

"It is easy for us to forget the power of words. We use them the way an engineer uses a slide rule or a surgeon uses a scalpel." – Jonathan Capehart, Pulitzer Prize winner, The Washington Post.

------

This article originally appeared on the University of Houston's The Big Idea.

Rene Cantu is the writer and editor at UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

Texas space co. takes giant step toward lunar excavator deployment

Out of this world

Lunar exploration and development are currently hampered by the fact that the moon is largely devoid of necessary infrastructure, like spaceports. Such amenities need to be constructed remotely by autonomous vehicles, and making effective devices that can survive the harsh lunar surface long enough to complete construction projects is daunting.

Enter San Antonio-based Astroport Space Technologies. Founded in San Antonio in 2020, the company has become a major part of building plans beyond Earth, via its prototype excavator, and in early February, it completed an important field test of its new lunar excavator.

The new excavator is designed to function with California-based Astrolab's Flexible Logistics and Exploration (FLEX) rover, a highly modular vehicle that will perform a variety of functions on the surface of the moon.

In a recent demo, the Astroport prototype excavator successfully integrated with FLEX and proceeded to dig in a simulated lunar surface. The excavator collected an average of 207 lbs (94kg) of regolith (lunar surface dust) in just 3.5 minutes. It will need that speed to move the estimated 3,723 tons (3,378 tonnes) of regolith needed for a lunar spaceport.

After the successful test, both Astroport and Astrolab expressed confidence that the excavator was ready for deployment. "Leading with this successful excavator demo proves that our technology is no longer theoretical—it is operational," said Sam Ximenes, CEO of Astroport.

"This is the first of many implements in development that will turn Astrolab's FLEX rover into the 'Swiss Army Knife' of lunar construction. To meet the infrastructure needs of the emerging lunar economy, we must build the 'Port' before the 'Ship' arrives. By leveraging the FLEX platform, we are providing the Space Force, NASA, and commercial partners with a 'Shovel-Ready' construction capability to secure the lunar high ground."

"We are excited to provide the mobility backbone for Astroport's groundbreaking construction technology," said Jaret Matthews, CEO of Astrolab, in a release. "Astrolab is dedicated to establishing a viable lunar ecosystem. By combining our FLEX rover's versatility with Astroport's civil engineering expertise, we are delivering the essential capabilities required for a sustainable lunar economy."

---

This article originally appeared on CultureMap.com.

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.